- Home
- RNAC vs TLSA Comparison
RNAC vs TLSA Comparison
Compare RNAC & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RNAC | TLSA |
|---|---|---|
| Founded | 2007 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 175.8M | 182.7M |
| IPO Year | 2016 | 2000 |
Fundamental Metrics
Financial Performance| Metric | RNAC | TLSA |
|---|---|---|
| Price | $7.47 | $1.73 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $38.80 | N/A |
| AVG Volume (30 Days) | 191.8K | ★ 282.7K |
| Earning Date | 11-06-2025 | 05-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,091,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.98 | $0.63 |
| 52 Week High | $20.12 | $2.60 |
Technical Indicators
Market Signals| Indicator | RNAC | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 50.60 | 57.68 |
| Support Level | $7.18 | $1.32 |
| Resistance Level | $8.34 | $1.58 |
| Average True Range (ATR) | 0.56 | 0.13 |
| MACD | 0.06 | 0.02 |
| Stochastic Oscillator | 55.67 | 82.56 |
Price Performance
Historical ComparisonAbout RNAC Cartesian Therapeutics Inc.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.